WVE WAVE Life Sciences

Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 p.m. ET.

A live webcast of the presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at . A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:

Kate Rausch

617-949-4827

Graham Morrell

781-686-9600

Media Contact:

Alicia Suter

617-949-4817

 

EN
28/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Yun Zhong
  • Yun Zhong

Adding To Best Ideas List and PT to $33; Just The Beginning of the Nex...

Recent Raise Has Strengthened Balance Sheet. WVE ended 3Q25 with total cash of $196.2M and raised $72.1M through ATM afterwards, which combined with committed GSK milestones extended the cash runway into 2Q27 (vs. previous guidance of into 2027). Earlier this week, WVE raised gross proceeds of appr

Wave Life Sciences Ltd: 8 directors

Eight Directors at Wave Life Sciences Ltd sold after exercising options/sold 1,020,845 shares at between 13.473USD and 15.782USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch